[Surprised]

5
Comment
Favorite

Apple888
2022-02-15

[Surprised]

Why Did Moderna Stock Drop on Monday? Waning Sentiment on Vaccine Makers

Moderna closed as the worst performer in the S&P 500 as COVID-19 vaccine makers witnessed a selloff

Why Did Moderna Stock Drop on Monday? Waning Sentiment on Vaccine Makers

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

Top
Latest

No comments yet

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":9095683733,"tweetId":"9095683733","gmtCreate":1644895889540,"gmtModify":1676533973525,"author":{"id":3552793013435190,"idStr":"3552793013435190","authorId":3552793013435190,"authorIdStr":"3552793013435190","name":"Apple888","avatar":"https://static.tigerbbs.com/3cd881eacfe2b6de7045a1744276477c","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":20,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p><span>[Surprised]&nbsp;</span></p></body></html>","htmlText":"<html><head></head><body><p><span>[Surprised]&nbsp;</span></p></body></html>","text":"[Surprised]","highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/9095683733","repostId":2211029965,"repostType":4,"repost":{"id":"2211029965","pubTimestamp":1644894043,"share":"https://www.laohu8.com/m/news/2211029965?lang=&edition=full","pubTime":"2022-02-15 11:00","market":"us","language":"en","title":"Why Did Moderna Stock Drop on Monday? Waning Sentiment on Vaccine Makers","url":"https://stock-news.laohu8.com/highlight/detail?id=2211029965","media":"seekingalpha","summary":"Moderna  closed as the worst performer in the S&P 500 as COVID-19 vaccine makers witnessed a selloff","content":"<html><head></head><body><p><a href=\"https://laohu8.com/S/MRNA\">Moderna </a> closed as the worst performer in the S&amp;P 500 as COVID-19 vaccine makers witnessed a selloff on Monday. With the biggest decline in more than two months, the shares of the Cambridge, Massachusetts-based biotech reached a 10-week low on above-average volume.</p><p>The investor sentiment is not the favor of COVID-19 vaccine developers, and Moderna (MRNA) in particular, after a pandemic-driven rally in 2020 and most of 2021.</p><p>COVID-19 cases in the U.S. are moving in a positive direction. As of Monday, the case numbers are on a negative trend in every state, according to the latest data from Johns Hopkins University. The average daily case numbers are hovering at 175,000 new cases per day, according to the Centers for Disease Control and Prevention (CDC).</p><p>While the average daily deaths remain elevated at 2,200, Moderna’s (MRNA) biggest rival in vaccine development, Pfizer (NYSE:PFE), is well-positioned to serve a potential post-pandemic scenario with its COVID-19 pill, Paxlovid, which is authorized in the U.S. for at-home use.</p><p>However, last week <a href=\"https://laohu8.com/S/PFE\">Pfizer </a> set its 2022 outlook below expectations even after raising the revenue guidance for the COVID-19 shot to ~$32B. The initial estimate for Paxlovid stood at $22B.</p><p>Today’s selloff comes after the U.S. Food and Drug Administration (FDA) decided to postpone an AdCom meeting scheduled to discuss the Pfizer (PFE)/BioNTech (NASDAQ:BNTX) COVID-19 vaccine for kids aged 6 months to 5 years after the drugmakers needed additional data from an ongoing study.</p><p>However, even after eight months from its request to the regulator, Moderna (MRNA) has yet to win the FDA approval for its COVID-19 vaccine for adolescents, an age category currently served by Pfizer (PFE) and <a href=\"https://laohu8.com/S/BNTX\">BioNTech </a>.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Did Moderna Stock Drop on Monday? Waning Sentiment on Vaccine Makers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Did Moderna Stock Drop on Monday? Waning Sentiment on Vaccine Makers\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-15 11:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3799785-why-did-moderna-stock-drop-today-waning-sentiment-on-vaccine-makers><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna  closed as the worst performer in the S&P 500 as COVID-19 vaccine makers witnessed a selloff on Monday. With the biggest decline in more than two months, the shares of the Cambridge, ...</p>\n\n<a href=\"https://seekingalpha.com/news/3799785-why-did-moderna-stock-drop-today-waning-sentiment-on-vaccine-makers\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4534":"瑞士信贷持仓","BK4548":"巴美列捷福持仓","BK4139":"生物科技","BK4551":"寇图资本持仓","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4533":"AQR资本管理(全球第二大对冲基金)","MRNA":"Moderna, Inc.","BK4007":"制药","BK4532":"文艺复兴科技持仓","BNTX":"BioNTech SE","PFE":"辉瑞","BK4535":"淡马锡持仓"},"source_url":"https://seekingalpha.com/news/3799785-why-did-moderna-stock-drop-today-waning-sentiment-on-vaccine-makers","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2211029965","content_text":"Moderna  closed as the worst performer in the S&P 500 as COVID-19 vaccine makers witnessed a selloff on Monday. With the biggest decline in more than two months, the shares of the Cambridge, Massachusetts-based biotech reached a 10-week low on above-average volume.The investor sentiment is not the favor of COVID-19 vaccine developers, and Moderna (MRNA) in particular, after a pandemic-driven rally in 2020 and most of 2021.COVID-19 cases in the U.S. are moving in a positive direction. As of Monday, the case numbers are on a negative trend in every state, according to the latest data from Johns Hopkins University. The average daily case numbers are hovering at 175,000 new cases per day, according to the Centers for Disease Control and Prevention (CDC).While the average daily deaths remain elevated at 2,200, Moderna’s (MRNA) biggest rival in vaccine development, Pfizer (NYSE:PFE), is well-positioned to serve a potential post-pandemic scenario with its COVID-19 pill, Paxlovid, which is authorized in the U.S. for at-home use.However, last week Pfizer  set its 2022 outlook below expectations even after raising the revenue guidance for the COVID-19 shot to ~$32B. The initial estimate for Paxlovid stood at $22B.Today’s selloff comes after the U.S. Food and Drug Administration (FDA) decided to postpone an AdCom meeting scheduled to discuss the Pfizer (PFE)/BioNTech (NASDAQ:BNTX) COVID-19 vaccine for kids aged 6 months to 5 years after the drugmakers needed additional data from an ongoing study.However, even after eight months from its request to the regulator, Moderna (MRNA) has yet to win the FDA approval for its COVID-19 vaccine for adolescents, an age category currently served by Pfizer (PFE) and BioNTech .","news_type":1},"isVote":1,"tweetType":1,"viewCount":246,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":11,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}